Fortress Biotech, Inc. · NASDAQ:FBIO

Fortress Biotech — Cyprium Therapeutics — Investor Presentation (June 2026)

14 slides from Fortress Biotech's investor presentation, June 2026

  1. Slide 1: Corporate Presentation June 2026

    Corporate Presentation June 2026

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Some statements in this presentation that are not descriptions of fact may be forward-looking statements, for which we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such statements

  3. Slide 3: Cyprium Overview

    Cyprium Overview ZYCUBO® (Copper Histidinate Injection) ▪ NDA approved January 2026 ▪ FDA granted RPD Priority Review Voucher (PRV) – announced the closing of the sale of the PRV for $205M in March 2026 Cyprium Therapeutics is focused on the development of novel therapies for the treatment of Menkes

  4. Slide 4: ZYCUBO for Menkes Disease (marketed by Sentynl)

    ZYCUBO® for Menkes Disease (marketed by Sentynl) ODD FT RPD BTD OMP ▪ ZYCUBO (Copper Histidinate Injection, formerly CUTX-101) ▪ NDA approved January 2026 ▪ FDA granted Priority Review Voucher (PRV) at approval; Sentynl transferred PRV to Cyprium ▪ Cyprium sold the PRV for $205M in March 2026 ▪ Sent

  5. Slide 5: AAV-ATP7A Gene Therapy for Menkes Disease

    AAV-ATP7A Gene Therapy for Menkes Disease ▪ Mottled–brindled mouse model recapitulates the disease phenotype ▪ Atp7amo-br phenotype ▪ A 6 bp in-frame deletion in exon 11 of Atp7a ▪ Depigmented coat color and curly whiskers ▪ Premature death (~13 days of age) ▪ Poor growth; Neurological symptoms ▪ Lo

  6. Slide 6: Copper is Required in Human Development and Health

    Copper is Required in Human Development and Health Biological Functions Copper Containing Proteins Brain Development Catecholamine production Dopamine -hydroxylase Mitochondrial respiration Cytochrome C oxidase Iron and copper transport Ceruloplasmin Peptide amidation Peptidylglycine -amidating mo

  7. Slide 7: Menkes Disease is a Rare Pediatric Disease Causing a Disorder of Copper Metabolism

    Menkes Disease is a Rare Pediatric Disease Causing a Disorder of Copper Metabolism Menkes Disease ▪ First described by Dr. John Menkes in 1962 ▪ X-linked recessive disease: affecting mostly boys ▪ Minimum birth prevalence for Menkes disease believed to be 1 in 34,810 live male births, but could pote

  8. Slide 8: Menkes Disease is Under-estimated and Under-diagnosed

    Menkes Disease is Under-estimated and Under-diagnosed New study estimated birth prevalence of Menkes disease based on the Genome Aggregation Database ▪ Accessed Genome Aggregation Database (gnomAD) at MIT/Broad Institute → over 200,000 ATP7A alleles ▪ Identified 1,106 ATP7A variants ▪ 4 Loss-of-Func

  9. Slide 9: Copper Transport is Impaired in Menkes Disease

    Copper Transport is Impaired in Menkes Disease Impaired Cu2+ transport to the Menkes brain via ATP7A Disease D D D D Impaired GI absorption via ATP7A Adapted from: Bandmann et al, Lancet Neuro 2015 9

  10. Slide 10: Therapeutic Strategy for Menkes Disease: ZYCUBO (Copper Histidinate)

    Therapeutic Strategy for Menkes Disease: ZYCUBO (Copper Histidinate) Impaired Cu2+ 1 transport to the ZYCUBO (Copper Histidinate (CuHis) ) Menkes brain via ATP7A SC injection to replenish CuHis Disease ▪ Bypass GI absorption of Cu2+ (impaired in Menkes patients) D ▪ Better tolerability (pH 7.4) ▪ Ma

  11. Slide 11: Therapeutic Strategy: ZYCUBO + AAV-ATP7A Gene Therapy

    Therapeutic Strategy for Menkes Disease: ZYCUBO (Copper Histidinate) + AAV-ATP7A Gene Therapy Restored Cu2+ transport to the 1 brain via ATP7A ZYCUBO Copper Histidinate Menkes gene therapy SC injection to replenish CuHis Disease ▪ Bypass GI absorption of Cu2+ (impaired in Menkes patients) D ▪ Better

  12. Slide 12: ZYCUBO efficacy in Early Treatment Cohort

    ZYCUBO efficacy in Early Treatment Cohort ▪ Patients in the ZYCUBO-ET cohort (patients treated with ZYCUBO) had a significant improvement in overall survival compared to patients in the EC-ET cohort, with a 78% reduction in the risk of death. ▪ In the ZYCUBO-ET cohort, 15 (48%) patients survived >6

  13. Slide 13: ZYCUBO efficacy in Late Treatment Cohort

    ZYCUBO efficacy in Late Treatment Cohort ▪ Patients in the ZYCUBO-LT cohort (patients treated with ZYCUBO) had a significant improvement in overall survival compared to patients in the EC-LT cohort, with a 73% reduction in the risk of death. Late-treatment cohort initiated treatment with ZYCUBO afte

  14. Slide 14: Thank you!

    Thank you! Investor Contacts: Cyprium Therapeutics, Inc. Jaclyn Jaffe, Investor Relations ir@cypriumtx.com 14

Cyprium Therapeutics — Investor Presentation (June 2026) on 6ix